ScienceWish

Author: Sciencewish

  • Published Works

    photo_2025-01-04_20-39-47-768x945
    exosomes-low quality-0۱
    Ang-Alrez-low-0۱
    photo_۲۰۲۵-۰۱-۰۵_۱۲-۵۸-۰۹
    photo_2025-01-04_20-03-55
    photo_2025-01-04_20-23-50
    photo_2025-01-04_20-32-15

  • TME as a therapeutic target

    In this article, we explored the tumor microenvironment (TME) potential as a therapeutic target for drug development. The TME, composed of a complex network of stromal, immune, and leukemic cells, contributes significantly to disease progression and resistance to conventional therapies, including multi-drug resistance (MDR). The article discusses how interactions within the TME facilitate leukemic cell survival and proliferation, and presents emerging targeted therapies designed to disrupt these interactions. By focusing on specific components and signaling pathways in the TME, such as WNT signaling, BCR inhibitors, and immune checkpoint blockade therapies, this research aims to uncover novel treatment strategies to complement traditional anti-leukemic treatments and improve patient outcomes.

  • Oncolytic viruses for cancer therapy

    [Figures are illustrated by me]

                                       
    In this study, Rezaei’s group explored how viruses interact with host cells, focusing on the identification of viral genes that are essential for replication in normal cells but dispensable in cancerous ones. this study aimed to improve oncolytic viruses for cancer therapy by removing unnecessary or harmful viral genes and inserting immune-boosting transgenes. The researchers used the Sleeping Beauty transposon system and nanopore sequencing to identify stable insertion sites and dispensable genes in HSV-1 and vaccinia virus. Their strategy makes it faster and easier to design safer and more effective therapeutic viruses.

  • Zanzalintinib as a Multi-Targeted Therapeutic Agent

    [Figures are illustrated by me]

                                                                                           
    In This article we focused on the therapeutic potential of Zanzalintinib (XL092) as a multi-targeted tyrosine kinase inhibitor (TKI) with both anti-angiogenic and immunomodulatory properties. It highlights how Zanzalintinib, particularly in combination with immune checkpoint inhibitors (ICIs), may offer a promising strategy for treating various solid tumors by targeting key signaling pathways such as MET and TAM kinases. By reviewing preclinical and clinical data, the article underscores efforts to identify new therapeutic targets and emphasizes the ongoing search for predictive biomarkers that can guide and optimize targeted drug development in oncology.

  • SHP2 as a therapeutic target

    In this article, we explored the potential of SHP2, a key signaling phosphatase, as a therapeutic target in cancer treatment—particularly in overcoming resistance to immune checkpoint therapies. By reviewing current research and combinatorial strategies, the study highlights how inhibiting SHP2 can disrupt cancer-promoting pathways and re-sensitize tumors to immunotherapy. The paper emphasizes SHP2’s central role in both tumor and immune cells, presenting it as a promising druggable node for future targeted therapies.

  • Uncovering New Targets in CRC: The Role of Omega-3 PUFAs in Tumor Immunity

    This review explores how polyunsaturated fatty acids (PUFAs), especially omega-3 types, interact with key inflammatory and immune pathways in colorectal cancer (CRC). By examining the molecular mechanisms behind PUFA action, the study sheds light on their potential to influence tumorigenic signaling, immune responses, and therapeutic outcomes. The authors suggest that understanding these interactions could guide the development of novel therapeutic targets and inform combinatory strategies involving PUFAs with immune checkpoint inhibitors or targeted therapies—marking an important step toward more precise and effective interventions for CRC.

  • Stunning colors in my MTT assay

    colors 😍😍😍